These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

646 related items for PubMed ID: 31919861

  • 1. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N, Altawalah H, Alfouzan W, Al-Nakib W, Al-Roumi E, Jeragh A.
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, Abdinia B, Shamshiri AR, Khairkhah M, Shekari Ebrahimabad H, Karimi A.
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [Abstract] [Full Text] [Related]

  • 7. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.
    Poethko-Müller C, Mankertz A.
    PLoS One; 2012 Jan; 7(8):e42867. PubMed ID: 22880124
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H.
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
    Mossong J, Putz L, Schneider F.
    Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584
    [Abstract] [Full Text] [Related]

  • 13. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L, Germann D, Bally F, Schopfer K.
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Study of mumps immunity after administrating measles-mumps-rubella vaccine among children aged 2-7 years old in Jiangsu Province in 2015].
    Liu YB, Hu Y, Deng XY, Wang ZG, Sun X, Lu PS, Guo HX, Tang FY, Zhou MH.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul 06; 51(7):593-597. PubMed ID: 28693082
    [Abstract] [Full Text] [Related]

  • 18. Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory.
    Ghafoori F, Mokhtari-Azad T, Foroushani AR, Farahmand M, Shadab A, Salimi V.
    BMC Infect Dis; 2024 Jul 12; 24(1):696. PubMed ID: 38997625
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.